Study guide
13.2 Derivation of Reference Values: RfD, RfC, ADI, TDI & Permissible Daily Exposure (PDE)
DABT: Diplomate of the American Board of Toxicology Exam
Track your progress as you read
Finished sections get a check mark.
1 Exam Overview & Study Design Fundamentals
1.1 Current DABT Exam Facts 1.2 Study Objectives, Hypothesis Testing & Regulatory Guideline Selection 1.3 Test System Selection, Species Models & Animal Welfare (3Rs, IACUC) 1.4 Route Selection, Dosing Regimens & Treatment Duration
2 Dose Selection, Controls & Biostatistics in Toxicology
2.1 Dose Selection Strategies: Range-Finding, Maximum Tolerated Dose (MTD) & Limit Doses 2.2 Control Groups (Negative, Vehicle, Positive, Sham) & Confounding Factors 2.3 Statistical Design, Power Analysis & Statistical Testing of Toxicological Data
3 Study Execution, GLP Compliance & Quality Assurance
3.1 Good Laboratory Practice (GLP) Regulations (FDA 21 CFR Part 58, OECD GLP) & Study Director Responsibilities 3.2 Test Article Characterization, Formulation Analysis, Stability & Homogeneity 3.3 Standard Operating Procedures (SOPs), Quality Assurance Unit (QAU) & Audit Inspections
4 Executing In Vivo, In Vitro, In Silico & Field Studies
4.1 In-Life Clinical Signs, FOB, Body Weight, Food/Water, Ophthalmology 4.2 In Vitro, In Silico (QSAR, Read-Across, PBPK, AI/ML), Field, Clinical & Epidemiologic Characterization
5 Clinical Pathology & Toxicologic Pathology
5.1 Hematology & Coagulation Parameters in Safety Evaluation 5.2 Clinical Chemistry: Biomarkers of Hepatic, Renal & Muscle Injury 5.3 Urinalysis & Specialized Biomarkers of Organ Toxicity 5.4 Toxicologic Pathology: Organ Weights, Gross Necropsy & Histopathology Interpretation
6 Specialized Toxicological Study Endpoints
6.1 Genetic Toxicology Assays: Ames Test, Chromosomal Aberrations & Micronucleus Assays 6.2 Reproductive & Developmental Toxicity Testing (ICH S5, Segments I, II, III) 6.3 Carcinogenicity Bioassays: Design, Conduct & Neoplastic Lesion Evaluation 6.4 Safety Pharmacology (Core Battery: Cardiovascular/hERG, CNS, Respiratory) & Immunotoxicology
7 Toxicokinetics & Biotransformation
7.1 Absorption & Physiological Barriers (Membrane Transport, Blood-Brain Barrier, GI Absorption) 7.2 Distribution, Plasma Protein Binding & Transporters (P-gp, OATs, OCTs, BSEP) 7.3 Phase I Biotransformation: Cytochrome P450 Monooxygenases & Non-CYP Oxidation 7.4 Phase II Biotransformation: Conjugation Pathways, Bioactivation & Detoxification
8 Cellular Mechanisms of Toxicity & Organ Pathogenesis
8.1 Oxidative Stress, Reactive Oxygen/Nitrogen Species (ROS/RNS) & Antioxidant Defenses 8.2 Cell Death Pathways: Necrosis, Apoptosis, Autophagy & Mitochondrial Dysfunction 8.3 Molecular Mechanisms of Target Organ Toxicity: Hepatotoxicity, Nephrotoxicity & Neurotoxicity
9 Hazard Identification & Evidence Integration
9.1 Hazard Identification Principles, Weight of Evidence (WoE) & Systematic Review 9.2 Carcinogen Hazard Classification Schemes (IARC, EPA Guidelines, GHS) 9.3 Agent Classes & Organ-System Toxic Responses
10 Mode of Action, AOPs & Non-Cancer Endpoints
10.1 Mode of Action (MoA) Framework & Human Relevance Evaluation 10.2 Adverse Outcome Pathways (AOP): Molecular Initiating Events, Key Events & Organ-Level Outcomes 10.3 Non-Cancer Systemic Toxicity Endpoints & Target Organ Critical Effects
11 Exposure Assessment Methodologies & Quantification
11.1 Exposure Routes, Scenarios & Pathways (Occupational, Dietary, Environmental, Consumer) 11.2 Exposure Quantification: Dose Equations, Average Daily Dose (ADD) & Lifetime Average Daily Dose (LADD) 11.3 Inhalation Dosimetry: Human Equivalent Concentrations (HEC) & Regional Gas Dose Ratios (RGDR) 11.4 Biomonitoring, Internal Dose, Fate/Transport & BCF
12 Quantitative Dose-Response Principles & Point of Departure Derivation
12.1 Dose-Response Relationships: Threshold vs Non-Threshold, Linear vs Non-Linear Models 12.2 Point of Departure (PoD) Determination: NOAEL, LOAEL & Benchmark Dose (BMD/BMDL) Modeling 12.3 Low-Dose Extrapolation, Cancer Slope Factors (CSF), Unit Risk & First-in-Human Dose
13 Health-Based Guidance Value Derivation & Uncertainty Factors
13.1 Uncertainty Factors (UFs), Interspecies/Intraspecies Extrapolation & Chemical-Specific Adjustment Factors (CSAF) 13.2 Derivation of Reference Values: RfD, RfC, ADI, TDI & Permissible Daily Exposure (PDE)
14 Risk Characterization for Non-Cancer & Cancer Health Effects
14.1 Non-Cancer Risk Characterization: Hazard Quotient (HQ), Hazard Index (HI) & Margin of Exposure (MoE) 14.2 Cancer Risk Characterization: Excess Lifetime Cancer Risk & Acceptable Risk Tolerances 14.3 Uncertainty & Sensitivity Analysis in Risk Characterization
15 Risk Management, Occupational Exposure Limits & Environmental Standards
15.1 Occupational Exposure Limit (OEL) Derivation: OSHA PELs, ACGIH TLVs & NIOSH RELs 15.2 Environmental Quality Standards: Drinking Water MCLs & Air Quality Standards (NAAQS) 15.3 Risk Management Decision-Making, Risk Communication & Socioeconomic Considerations
16 Regulatory Frameworks & Product Stewardship
16.1 Food, Drug & Cosmetic Regulation: FDA Framework, Delaney Clause & GRAS Evaluations 16.2 Chemical Substances & Environmental Regulation: EPA TSCA, FIFRA, Clean Air & Clean Water Acts 16.3 International Regulatory Harmonization: OECD, ICH Guidelines & EU REACH
17 Clinical Toxicology & Medical Management of Poisoning
17.1 Clinical Toxidromes & Initial Management of Acute Poisoning 17.2 Specific Antidotes, Mechanisms of Action & Decontamination Strategies
18 Environmental, Ecological & Public Health Toxicology
18.1 Environmental Toxicology: Fate, Transport, Bioaccumulation (log Kow, BCF) & Ecotoxicological Testing 18.2 Public Health Events, Epidemiology, Susceptible Subpopulations & Exposure Investigation
13.2 Derivation of Reference Values: RfD, RfC, ADI, TDI & Permissible Daily Exposure (PDE)
Key Takeaways Explain This Topic AI
RfD = PoD / (UF × MF) in mg/kg-day; RfC is the inhalation analog in mg/m3 after HEC dosimetry. EPA defines the RfD as a lifetime daily oral estimate for the population including sensitive subgroups, with uncertainty of perhaps an order of magnitude.
Worked RfD: BMDL10 2.5 mg/kg-day divided by UFs 10 × 10 × 3 = 300 equals 0.0083 mg/kg-day (2.5/300 = 0.008333…). Multiplying 2.5 × 300, dividing by 30, or dividing by 1,000 are arithmetic errors.
ADI (JECFA/FDA) is for intentional food uses; TDI is for unavoidable contaminants; ICH Q3C PDE (mg/day) = (NOEL × 50 kg) / (F1 × F2 × F3 × F4 × F5) for residual solvents, with F1 species factors such as rat 5 and mouse 12 and F2 = 10.
TTC screening values from Munro/Kroes/EFSA include Cramer Class I/II/III at 1,800, 540, and 90 µg/person/day. ICH M7 lifetime TTC for most mutagenic impurities is 1.5 µg/day (about 10^−5); the Kroes/EFSA DNA-reactive food TTC is 0.15 µg/day (about 10^−6). Cohort of concern is excluded.
REACH DNEL = dose descriptor / assessment factors (threshold). DMEL is a non-threshold, risk-based construct; ECHA R.8 discusses indicative extra-risk figures near 10^−5 (workers) and 10^−6 (general population), not an EU statute. Health-based OELs use a worker receptor; derivation detail is Chapter 15.
Last updated: September 2026
The reference value is the PoD after the factors
Handbook III.C.3 F asks you to name the number that exposure will be compared with: reference dose (RfD) , reference concentration (RfC) , acceptable daily intake (ADI) , tolerable daily intake (TDI) , permissible daily exposure (PDE) , screening thresholds of toxicological concern (TTC) , and under REACH a derived no-effect level (DNEL) or derived minimal-effect level (DMEL) . Independent ExamFinch teaching derives those constructs, works the RfD arithmetic the examination expects, and flags health-based occupational exposure limits (OELs) as the same family with a worker receptor—detail belongs in Chapter 15 . This section is not an ABT, EPA, FDA, JECFA, ICH, EFSA, or ECHA product and does not claim official approval, review, or partnership with those bodies.
Chapter 12 gave you a PoD. Section 13.1 gave you UFs. This section divides .
RfD and RfC
EPA IRIS definition of an RfD : an estimate ( with uncertainty spanning perhaps an order of magnitude ) of a daily oral exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime .
RfD = PoD / (UF × MF)
Units: mg/kg-day (sometimes written mg/kg/day). Compare with oral average daily dose (ADD) from Chapter 11, not with a lifetime cancer LADD unless you are in the wrong playbook.
RfC is the inhalation analog: same definition, units mg/m³ (sometimes converted to ppm for a gas). Compare with an exposure concentration , not with a mg/kg “inhalation intake” from old RAGS Part A. After HEC dosimetry, the formula is still
RfC = PoD_HEC / (UF × MF)
Worked RfD (required arithmetic). Critical-effect BMDL10 = 2.5 mg/kg-day . Uncertainty factors UFA = 10 , UFH = 10 , UFS = 3 ; UFL = UFD = MF = 1 .
Composite UF = 10 × 10 × 3 = 300
RfD = 2.5 / 300 = 0.008333… mg/kg-day , which reports as 0.0083 mg/kg-day (or 8.3 × 10^−3 mg/kg-day ).
Checks:
300 × 0.008333… = 2.50 exactly (2.5 ÷ 300 = 1/120).
300 × 0.0083 = 2.49 , within ordinary rounding of 2.50.
For a 70 kg adult, implied milligrams per day = 0.0083 × 70 = 0.581 mg/day . For 60 kg : 0.0083 × 60 = 0.498 mg/day . Those daily milligrams are a communication aid . The RfD remains 0.0083 mg/kg-day .
Failure modes:
2.5 / 30 = 0.083 — dropped one 10.
2.5 / 1,000 = 0.0025 — used three full tens (10 × 10 × 10) instead of 10 × 10 × 3.
2.5 × 300 = 750 — multiplied. An RfD cannot be larger than the BMDL10 unless a data-derived factor is < 1 ; a default stack is not.
2.5 / 23 = 0.109 — added 10 + 10 + 3.
Using 2.5 / 300 as an RfC in mg/m³ without dosimetry.
If this BMDL had already been converted to an HED of 2.5 mg/kg-day , UFA should have been the residual 3 , not 10. The problem as written uses 10 × 10 × 3 , which is the administered-dose-style stack (full interspecies 10, full human 10, partial duration 3). Read the item stem: did they already make an HED?
RfC teaching twin. HEC BMDL = 2.5 mg/m³ , same UF 300 : RfC = 2.5 / 300 = 0.0083 mg/m³ . Same arithmetic, different unit and route . Do not compare that RfC with an oral ADD.
ADI, TDI, and PDE
These are cousins , not synonyms.
Construct Who typically issues it Used for Formula family Units
RfD / RfC EPA IRIS and program offices Environmental chemicals; some EPA pesticide values PoD / (UF × MF) mg/kg-day or mg/m³
ADI JECFA , FDA , JMPR Intentional food additives; residues of use-authorized pesticides Often chronic NOAEL / 100 (10 × 10) mg/kg bw/day
TDI (or TWI weekly) JECFA, EFSA, national food agencies Unavoidable contaminants (metals, process contaminants) Same UF idea; wording is “tolerable,” not “acceptable” mg/kg-day or µg/kg-day
PDE ICH Q3C (residual solvents); cousins in Q3D elemental impurities Pharmaceutical impurities / residual solvents (NOEL × 50 kg) / (F1 × F2 × F3 × F4 × F5) mg/day
TTC Kroes, Munro, EFSA , ICH M7 Screening when chemical-specific data are thin Structure class or mutagenic default, not a PoD/UF derivation µg/day or µg/kg-day
DNEL / DMEL REACH registrants, ECHA R.8 EU chemical safety assessment Dose descriptor / assessment factors ; DMEL is risk-based mg/m³, mg/kg-day, or dermal mg/kg/day
Health-based OEL ACGIH, NIOSH, SCOEL/RAC; OSHA PELs are often outdated legal numbers Workers , 8-hour TWA Related UF/AF logic; Chapter 15 ppm or mg/m³
ADI versus TDI. Acceptable is the word for a substance society chose to add (a colorant, a sweetener, a pesticide used according to label). Tolerable is the word for a substance nobody wants in food but that is hard to drive to zero (lead, cadmium, some process-formed contaminants). Numerically both are often NOAEL/100 when a chronic animal NOAEL is the PoD and only inter- and intra-species 10s are applied. Calling a food-additive ADI a contaminant TDI is a vocabulary error the examination will score. Provisional TDI/TWI means the committee is waiting on data.
FDA uses ADI language in food-additive and some veterinary-residue settings. It is not an EPA RfD. Same 100-fold habit, different statute.
ICH Q3C PDE (F1–F5)
Permissible daily exposure for a residual solvent :
PDE (mg/day) = (NOEL × weight adjustment) / (F1 × F2 × F3 × F4 × F5)
Weight adjustment = 50 kg (ICH’s deliberately low adult mass; 60 or 70 kg would give a larger PDE). Pediatric products need a lower mass .
- Factor Role Teaching values
- F1 Species (surface-area ratios) Mouse 12 , rat 5 , monkey 3 , dog 2 , rabbit 2.5 , other animals 10
- F2 Individual humans 10 for all organic solvents in Q3C
F3 Short study 1 if at least half-lifetime (1 year rodent; 7 years dog/monkey) or a full organogenesis reproductive study; 2 for 6-month rodent / 3.5-year nonrodent; 5 for 3-month rodent / 2-year nonrodent; 10 if shorter
F4 Severe toxicity 1–10 ; reproductive: 1 fetal toxicity with maternal toxicity; 5 fetal toxicity without maternal, or teratogenicity with maternal; 10 teratogenicity without maternal; also used for neurotoxicity or nongenotoxic carcinogenicity
F5 No NOEL 1 if NOEL exists; up to 10 if only a LOEL, scaled by severity
Worked PDE. Rat oral NOEL = 50 mg/kg/day , 90-day study, no severe toxicity, NOEL established.
- F1 = 5 , F2 = 10 , F3 = 5 (3-month rodent), F4 = 1 , F5 = 1
- Denominator = 5 × 10 × 5 × 1 × 1 = 250
- Numerator = 50 × 50 = 2,500
- PDE = 2,500 / 250 = 10 mg/day
Option 1 concentration (assumes 10 g/day drug product): ppm = 1,000 × PDE / dose = 1,000 × 10 / 10 = 1,000 ppm .
If the same NOEL came from mice , F1 = 12 , denominator = 12 × 10 × 5 = 600 , PDE = 2,500 / 600 = 4.17 mg/day . Species factor matters.
Q3C Class 1 solvents (benzene, carbon tetrachloride, others) are avoid / tight toxicology-specific limits, not this generic PDE recipe. Class 3 solvents with low toxic potential are often controlled at 5,000 ppm or 50 mg/day without a full F1–F5 rebuild. Know which class you are in before grinding F3.
F1 5 for rat is a surface-area species factor. It is cousin to FDA 0.16 (because 1/5 = 0.20, near 0.16) and not EPA UFA . Do not multiply F1 = 5 and UFA = 10 and BW^0.75 on one solvent.
TTC and Cramer classes
When structure is known but chemical-specific toxicity is thin , threshold of toxicological concern is a screening intake . It is not an RfD for a data-rich pesticide.
Cramer et al. (1978) decision tree → Class I (simple structures, efficient metabolism, low oral toxicity), Class II (intermediate), Class III (reactive structures, no basis for presumption of safety). Munro et al. (1996) took 5th-percentile NOAELs in each class and divided by 100 to produce the classic oral TTC values. Kroes et al. added a decision tree for genotoxicity alerts and a cohort of concern . EFSA 2019 restated the numbers in µg/kg as well as µg/person, using 60 kg .
- Bucket TTC (µg/person/day) TTC (µg/kg-day) at 60 kg Source to cite carefully
- Cramer Class I 1,800 30 Munro / Kroes / EFSA
- Cramer Class II 540 9.0 Munro / Kroes / EFSA
- Cramer Class III 90 1.5 Munro / Kroes / EFSA
- Organophosphates and carbamates 18 0.3 Kroes / EFSA (more protective than Class III)
- DNA-reactive mutagen/carcinogen (food-style 10^−6 ) 0.15 0.0025 Kroes / EFSA
ICH M7 mutagenic impurity, lifetime , not cohort of concern 1.5 µg/day — ICH M7 (risk basis about 10^−5 , pharmaceutical context)
Checks on the Cramer µg/kg figures: 30 × 60 = 1,800 ; 9 × 60 = 540 ; 1.5 × 60 = 90 . Those multiplications are how the per-person and per-kg columns stay together.
Do not mix 0.15 with 1.5. The ten-fold difference is risk-level and context , not a rounding error. Food/public TTC for DNA-reactive chemicals is commonly 0.15 µg/day (about 10^−6 lifetime cancer risk in the Kroes calibration). ICH M7 sets 1.5 µg/day as the lifetime TTC for most mutagenic impurities in drugs (about 10^−5 ). Less-than-lifetime ICH M7 staged intakes are higher (for example 20 µg/day for 1–12 months and 120 µg/day for less than 1 month in widely cited M7 tables—learn that staging exists; confirm the current M7 table when you practice). Cohort of concern (aflatoxin-like, N-nitroso, alkyl-azoxy, and related high-potency groups named in the TTC tree) is excluded from TTC; those structures need compound-specific data.
If exposure is below TTC , the screening conclusion is low probability of appreciable risk , not “proven nontoxic.” If exposure is above TTC , you leave TTC and do a chemical-specific assessment (or generate data). TTC is not used when a regulation requires a full dossier (many food additives, pesticide active ingredients). Chapter 12 already used a compound-specific ICH M7 margin of 10,000 from a BMDL10; TTC 1.5 µg/day is the default when that BMDL does not exist , not a ceiling that overrides data.
REACH DNEL and DMEL
DNEL = (modified) dose descriptor / product of assessment factors . ECHA R.8 defaults (fallbacks, not a starting brag):
Interspecies: allometric (rat oral 4 ) × remaining 2.5
Intraspecies: 5 for workers , 10 for general population (workers treated as a healthier, adult, narrower group)
- Duration: 3 subacute to subchronic, 2 subchronic to chronic, 6 subacute to chronic
- LOAEL to NAEL: often 3 (sometimes 10)
- Quality of database: typically 1 , raised when the package is weak
DNEL is threshold language (irritation, liver hypertrophy with a practical threshold, reproductive NOAEL). Several DNELs may exist (worker inhalation long-term, worker dermal, general-population oral). The leading (lowest) DNEL for that exposure pattern is the one that drives risk characterization.
Worked worker DNEL (threshold). Same BMDL 2.5 mg/kg-day , rat oral, subchronic to chronic, NOAEL/BMDL so no LOAEL factor. Assessment factors: 4 × 2.5 × 5 × 2 = 100 . DNEL = 2.5 / 100 = 0.025 mg/kg-day , then converted to the worker route (inhalation or dermal) with absorption and ventilation as needed. The general-population twin replaces worker 5 with 10 , doubling the divisor to 200 and halving the DNEL to 0.0125 mg/kg-day .
DMEL is for non-threshold endpoints, typically genotoxic carcinogens where a true no-effect level is not assumed. It is a derived minimal-effect level— not a no-effect level. ECHA R.8 discusses indicative lifetime extra-risk figures of about 10^−5 for workers and 10^−6 for the general population as policy-flavored illustrations , not EU-wide legal “acceptable risk” statutes. The alternative R.8 path is a large assessment-factor on a cancer PoD. Writing “DMEL = DNEL with a bigger UF” misses the risk-specific nature of DMEL.
Health-based OELs (preview of Chapter 15)
An OEL (TLV, REL, some PELs, IOELV) is a workplace air number for a healthy-adult worker , usually an 8-hour time-weighted average , sometimes with a STEL or ceiling. Derivation looks like RfC/DNEL math (PoD, dosimetry, assessment factors) but the receptor, duration, and risk-management body differ. OSHA PELs are often outdated legally adopted values, not current health-based science. Do not take an RfC in mg/m³, multiply by 8/24, and call it a TLV. Chapter 15 is where PEL/TLV/REL procedures live.
Putting the worked RfD next to the other machines
Same BMDL10 = 2.5 mg/kg-day :
EPA RfD with UF 300 : 0.0083 mg/kg-day (this section’s required example).
JECFA-style ADI if a committee treated 2.5 as a chronic NOAEL and applied only 100 : 0.025 mg/kg-day . Different policy stack.
ICH PDE first converts 2.5 mg/kg-day × 50 kg = 125 mg/day , then divides by F1–F5 , not by EPA’s 300. If the F-product were 250 (rat 90-day, F4 = F5 = 1), PDE = 0.50 mg/day , which at 50 kg is 0.010 mg/kg-day —again, a different number.
TTC would ignore 2.5 if you had that BMDL; you already have chemical-specific data.
ICH M7 TTC 1.5 µg/day applies to a mutagenic impurity without a compound-specific PoD , not to this 2.5 mg/kg-day liver BMDL.
Scenario
A solvent has a rat 90-day BMDL10 of 2.5 mg/kg-day for hepatocellular hypertrophy. The IRIS-style RfD is 0.0083 mg/kg-day after 300 . The same laboratory number is used in a drug-substance residual-solvent file: Q3C F1 = 5, F2 = 10, F3 = 5, F4 = 1, F5 = 1 , PoD treated as a NOEL of 2.5 mg/kg/day , PDE = (2.5 × 50) / 250 = 125 / 250 = 0.50 mg/day . A REACH registrant builds a worker DNEL with allometric 4 × 2.5 , worker 5 , duration 2 : AF = 100 , DNEL = 2.5/100 = 0.025 mg/kg-day (then converted to inhalation). A food-contaminant panel publishes a TDI of 0.025 mg/kg-day (NOAEL-style 100). Four numbers from one BMDL. The DABT skill is naming which machine you are in , not averaging them.
A mutagenic impurity with no bioassay uses ICH M7 TTC 1.5 µg/day , not Cramer Class III 90 µg/day , and not the food genotox TTC 0.15 µg/day unless you are actually in that food-screening context.
Traps
Reporting RfD = 2.5/300 as 0.083 or 0.0025 , or as 750 .
Calling a contaminant limit an ADI, or a food-additive ADI a PDE.
Using 70 kg in a Q3C PDE when ICH specifies 50 kg .
Applying Cramer III 90 µg/day to an aflatoxin-like structure or to an ICH M7 mutagenic impurity.
Equating ICH M7 1.5 µg/day with Kroes 0.15 µg/day .
Treating DMEL as a threshold DNEL.
Converting an RfC into an OEL with a homemade 8/24 factor and calling it a TLV.